# Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)

> **NCT00687323** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 47 (actual)

## Conditions studied

- Leukemia, Acute Myeloid
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00687323
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-30
- **Primary completion:** 2011-05-09
- **Final completion:** 2012-12-23
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687323, "Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00687323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*